Publications

Mäser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel M.W, Kaiser M, Lengeler C, Pluschke G, Reus E, Rottmann M, Utzinger J, Warryn L, Wittlin S, Keiser J. Key contributions by the Swiss Tropical and Public Health Institute towards new and better drugs for tropical diseases. Chimia (Aarau). 2023;77(9):593-606. DOI: 10.2533/chimia.2023.593

Bernhard S, Kaiser M, Burri C, Mäser P. Fexinidazole for human African trypanosomiasis, the fruit of a successful public-private partnership. Diseases. 2022;10(4):90. DOI: 10.3390/diseases10040090

Mesu V.K.B.K, Kalonji W.M, Bardonneau C, Valverde Mordt O, Ngolo Tete D, Blesson S, Simon F, Delhomme S, Bernhard S, Nganzobo Ngima P, Mahenzi Mbembo H, Fina Lubaki J.P, Lumeya Vuvu S, Kuziena Mindele W, Ilunga Wa Kyhi M, Mandula Mokenge G, Kaninda Badibabi L, Kasongo Bonama A, Kavunga Lukula P, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial. Lancet Glob Health. 2022;10(11):e1665-e1674. DOI: 10.1016/S2214-109X(22)00338-2

Kümmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D.N, Kisala M, Burri C, Blesson S, Valverde Mordt O. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. PLoS Negl Trop Dis. 2021;15(11):e0009903. DOI: 10.1371/journal.pntd.0009903

Mesu V.K.B.K, Mutombo Kalonji W, Bardonneau C, Valverde Mordt O, Ngolo Tete D, Blesson S, Simon F, Delhomme S, Bernhard S, Mahenzi Mbembo H, Mpia Moke C, Lumeya Vuvu S, Mudji E'kitiak J, Akwaso Masa F, Mukendi Ilunga M, Mpoyi Muamba Nzambi D, Mayala Malu T, Kapongo Tshilumbwa S, Botalema Bolengi F, Nkieri Matsho M, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021;9(7):e999-e1008. DOI: 10.1016/s2214-109x(21)00208-4

Mesu V.K.B.K, Kalonji W.M, Bardonneau C, Mordt O.V, Blesson S, Simon F, Delhomme S, Bernhard S, Kuziena W, Lubaki J.F, Vuvu S.L, Ngima P.N, Mbembo H.M, Ilunga M, Bonama A.K, Heradi J.A, Solomo J.L.L, Mandula G, Badibabi L.K, Dama F.R, Lukula P.K, Tete D.N, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144-154. DOI: 10.1016/S0140-6736(17)32758-7

Burri C, Yeramian P.D, Allen J.L, Merolle A, Serge K.K, Mpanya A, Lutumba P, Mesu V.K, Bilenge C.M, Lubaki J.P, Mpoto A.M, Thompson M, Munungu B.F, Manuel F, Josenando T, Bernhard S.C, Olson C.A, Blum J, Tidwell R.R, Pohlig G. Efficacy, safety, and dose of pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies. PLoS Negl Trop Dis. 2016;10(2):e0004362. DOI: 10.1371/journal.pntd.0004362

Mordt O.V, Bernhard S, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Tete D, Nganzobo P, Mubwa N, Blésson S, Tarral A, Wourgaft N.S. Nifurtimox eflornithine combination therapy phase IIIb field trial (NECT Field): final effectiveness and safety results. Trop Med Int Health, 2015;20(Suppl. 1):325. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland

Mordt O.V, Bernhard S, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Tete D, Nganzobo P, Mubwa N, Blésson S, Tarral A. NECT feld phase IIIb trial: final effectiveness in adults and children results. Trop Med Int Health, 2013;18(Suppl. 1):59-60